Literature DB >> 15090833

Decline in HIV infectivity following the introduction of highly active antiretroviral therapy.

Travis C Porco1, Jeffrey N Martin, Kimberly A Page-Shafer, Amber Cheng, Edwin Charlebois, Robert M Grant, Dennis H Osmond.   

Abstract

OBJECTIVE: Little is known about the degree to which widespread use of antiretroviral therapy in a community reduces uninfected individuals' risk of acquiring HIV. We estimated the degree to which the probability of HIV infection from an infected partner (the infectivity) declined following the introduction of highly active antiretroviral therapy (HAART) in San Francisco.
DESIGN: Homosexual men from the San Francisco Young Men's Health Study, who were initially uninfected with HIV, were asked about sexual practices, and tested for HIV antibodies at each of four follow-up visits during a 6-year period spanning the advent of widespread use of HAART (1994-1999).
METHODS: We estimated the infectivity of HIV (per-partnership probability of transmission from an infected partner) using a probabilistic risk model based on observed incident infections and self-reported sexual risk behavior, and tested the hypothesis that infectivity was the same before and after HAART was introduced.
RESULTS: A total of 534 homosexual men were evaluated. Decreasing trends in HIV seroincidence were observed despite increases in reported number of unprotected receptive anal intercourse partners. Conservatively assuming a constant prevalence of HIV infection between 1994 and 1999, HIV infectivity decreased from 0.120 prior to widespread use of HAART, to 0.048 after the widespread use of HAART- a decline of 60% (P=0.028).
CONCLUSIONS: Use of HAART by infected persons in a community appears to reduce their infectiousness and therefore may provide an important HIV prevention tool.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15090833      PMCID: PMC2442908          DOI: 10.1097/00002030-200401020-00010

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  29 in total

1.  Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco.

Authors:  Mitchell H Katz; Sandra K Schwarcz; Timothy A Kellogg; Jeffrey D Klausner; James W Dilley; Steven Gibson; William McFarland
Journal:  Am J Public Health       Date:  2002-03       Impact factor: 9.308

2.  Modelling the effect of combination antiretroviral treatments on HIV incidence.

Authors:  M G Law; G Prestage; A Grulich; P Van de Ven; S Kippax
Journal:  AIDS       Date:  2001-07-06       Impact factor: 4.177

3.  Population- and individual-based approaches to the design and analysis of epidemiologic studies of sexually transmitted disease transmission.

Authors:  S Shiboski; N S Padian
Journal:  J Infect Dis       Date:  1996-10       Impact factor: 5.226

Review 4.  Ritonavir.

Authors:  A P Lea; D Faulds
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

5.  HIV transmission in sexual networks: an empirical analysis.

Authors:  S k Service; S M Blower
Journal:  Proc Biol Sci       Date:  1995-06-22       Impact factor: 5.349

6.  Can antiretroviral therapy be used to prevent sexual transmission of human immunodeficiency virus type 1?

Authors:  Mina Hosseinipour; Myron S Cohen; Pietro L Vernazza; Angela D M Kashuba
Journal:  Clin Infect Dis       Date:  2002-04-22       Impact factor: 9.079

7.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

Authors:  S M Hammer; K E Squires; M D Hughes; J M Grimes; L M Demeter; J S Currier; J J Eron; J E Feinberg; H H Balfour; L R Deyton; J A Chodakewitz; M A Fischl
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

8.  Projected incidence of AIDS in San Francisco: the peak and decline of the epidemic.

Authors:  G F Lemp; T C Porco; A M Hirozawa; M Lingo; G Woelffer; L C Hsu; M H Katz
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-11-01

9.  A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.

Authors:  S M Hammer; D A Katzenstein; M D Hughes; H Gundacker; R T Schooley; R H Haubrich; W K Henry; M M Lederman; J P Phair; M Niu; M S Hirsch; T C Merigan
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

Review 10.  Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection.

Authors:  S Noble; D Faulds
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

View more
  105 in total

1.  The cost-effectiveness of a modestly effective HIV vaccine in the United States.

Authors:  Elisa F Long; Douglas K Owens
Journal:  Vaccine       Date:  2011-04-19       Impact factor: 3.641

2.  An update on HIV related epidemiological research.

Authors:  Nicole H T M Dukers; Maria Prins; Roel A Coutinho
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

3.  The role of commercial sex venues in the HIV epidemic among men who have sex with men.

Authors:  William John Reidy; Steven Michael Goodreau
Journal:  Epidemiology       Date:  2010-05       Impact factor: 4.822

4.  Shifting the paradigm: using HIV surveillance data as a foundation for improving HIV care and preventing HIV infection.

Authors:  Patricia Sweeney; Lytt I Gardner; Kate Buchacz; Pamela Morse Garland; Michael J Mugavero; Jeffrey T Bosshart; R Luke Shouse; Jeanne Bertolli
Journal:  Milbank Q       Date:  2013-07-08       Impact factor: 4.911

Review 5.  Greater risk for HIV infection of black men who have sex with men: a critical literature review.

Authors:  Gregorio A Millett; John L Peterson; Richard J Wolitski; Ron Stall
Journal:  Am J Public Health       Date:  2006-05-02       Impact factor: 9.308

Review 6.  When to start antiretroviral therapy.

Authors:  Cunlin Wang; Saba W Masho; Daniel E Nixon
Journal:  Curr HIV/AIDS Rep       Date:  2006-07       Impact factor: 5.071

7.  Implications for HIV prevention programs from a serobehavioural survey of men who have sex with men in Vancouver, British Columbia: the ManCount study.

Authors:  David M Moore; Steve Kanters; Warren Michelow; Reka Gustafson; Robert S Hogg; Michael Kwag; Terry Trussler; Marissa McGuire; Wayne Robert; Mark Gilbert
Journal:  Can J Public Health       Date:  2012 Mar-Apr

8.  Patient characteristics and availability of onsite non-rapid and rapid HIV testing in US substance use disorder treatment programs.

Authors:  Amanda J Abraham; Lauren A O'Brien; Hannah K Knudsen; Brian E Bride; G Rush Smith; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2012-04-25

9.  Mental health treatment to reduce HIV transmission risk behavior: a positive prevention model.

Authors:  Kathleen J Sikkema; Melissa H Watt; Anya S Drabkin; Christina S Meade; Nathan B Hansen; Brian W Pence
Journal:  AIDS Behav       Date:  2010-04

Review 10.  Behavioral and biomedical combination strategies for HIV prevention.

Authors:  Linda-Gail Bekker; Chris Beyrer; Thomas C Quinn
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.